It takes approximately 12 weeks for Ilumya (tildrakizumab) to start working with nearly 60% of people experiencing a 75% reduction in the severity of their psoriasis within that time; however, it may take over a year for the full benefits to be seen.

Research has shown that after 12 weeks:

• 55% to 58% of people administered Ilumya had cleared or minimal disease according to their PGA (physicians global assessment) score compared to 4% to 7% of those administered placebo
• 61% to 64% had experienced a 75% reduction in their disease as defined by their PASI score
• 35% to 39% had experienced a 90% reduction in their disease as defined by their PASI score
• 12% to 14% had experienced a 100% reduction in their disease as defined by their PASI score.

Longer-term studies have indicated the percentage of people experiencing benefit increases with continued treatment.

• After 28 weeks of treatment, 74% of people administered Ilumya had experienced a 75% reduction in their disease as defined by their PASI score
• After 64 weeks of treatment, 84% of people administered Ilumya had experienced a 75% reduction in their disease as defined by their PASI score.

Some people who previously been assigned Ilumya in the trial were then given a placebo. It took an average of 20 weeks for the benefits of Ilumya to be lost once it had been discontinued.